Why Two Men on the Same Dose of Finasteride Can Get Completely Different Results

One of the more frustrating experiences in treating male pattern baldness is watching a close friend or colleague respond dramatically to finasteride while your own results remain modest — despite following the same protocol, taking the same dose, and giving the treatment the same amount of time. Clinicians have long acknowledged that individual response to finasteride varies considerably. What has taken longer to understand is precisely why.

The answer, at least in significant part, lies in your DNA.

The Enzyme at the Center of Everything

Finasteride works by inhibiting 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the androgen primarily responsible for miniaturizing hair follicles in genetically susceptible men. Block DHT production sufficiently, and follicle miniaturization slows or reverses. The clinical logic is straightforward.

What complicates this picture is what happens to finasteride itself after you swallow the tablet. Before the drug can exert its effect, it must be absorbed, distributed, and metabolized. That metabolic process is largely governed by a family of liver enzymes known as cytochrome P450 enzymes — specifically, CYP3A4 and, to a lesser degree, CYP1A2 and CYP2C9. These enzymes are responsible for breaking finasteride down into its inactive metabolites, which are then cleared from the body.

Here is where individual biology begins to matter enormously.

Genetic Polymorphisms and What They Mean for Drug Response

The genes encoding cytochrome P450 enzymes are not identical across the human population. Variations in these genes — known as single nucleotide polymorphisms, or SNPs — can produce enzymes that function at different speeds. Pharmacologists classify individuals based on their metabolizer status:

• Poor metabolizers carry gene variants that produce slower or less functional enzyme activity. Drugs that depend on these enzymes for clearance tend to accumulate to higher concentrations in the body.
• Extensive metabolizers (sometimes called normal metabolizers) process drugs at a standard rate, consistent with how most clinical trials are designed.
• Ultra-rapid metabolizers carry variants that produce highly active enzymes, clearing drugs from the system faster than average.

When applied to finasteride, this classification carries real implications. A poor metabolizer taking 1 mg of finasteride daily may maintain higher plasma concentrations of the drug compared to an ultra-rapid metabolizer on the identical regimen. Higher sustained concentrations may translate into more complete DHT suppression. Conversely, someone who clears finasteride rapidly may not maintain the drug levels necessary to achieve consistent 5-alpha reductase inhibition throughout the day.

This does not mean poor metabolizers always fare better — higher drug concentrations can also increase exposure to side effects. But it does suggest that the uniform 1 mg daily dose may be functionally different from person to person in ways that standard prescribing practices do not account for.

The Androgen Receptor Variable

Cytochrome P450 variation is only one piece of the genetic puzzle. Research has also identified polymorphisms in the androgen receptor gene — located on the X chromosome — that influence how sensitively hair follicles respond to DHT in the first place. Men who inherit variants associated with high androgen receptor sensitivity tend to experience more aggressive follicle miniaturization when DHT is present.

Significantly, this same sensitivity may also affect how robustly follicles respond when DHT is suppressed by finasteride. Some research suggests that men with high androgen receptor sensitivity may see more pronounced regrowth when DHT is adequately blocked, while others with lower baseline sensitivity may see less dramatic change even when the drug is working as intended.

The interplay between androgen receptor genetics and cytochrome P450 metabolism creates a layered biological context that helps explain the wide spectrum of clinical outcomes observed in real-world finasteride use — outcomes that large-scale trials, by their averaging nature, tend to obscure.

What Pharmacogenomics Research Is Beginning to Reveal

Pharmacogenomics — the study of how genetic variation influences drug response — has advanced considerably in recent years, driven in part by the declining cost of genetic sequencing and the growth of direct-to-consumer testing companies in the United States. While finasteride-specific pharmacogenomic guidelines have not yet been formally established by bodies such as the Clinical Pharmacogenomics Implementation Consortium (CPIC), researchers are actively investigating the relationship between CYP3A4 variants and finasteride efficacy.

Some dermatology researchers have proposed that pre-treatment genetic testing could eventually allow clinicians to stratify patients — identifying those likely to be strong responders, those who may need dosage adjustments, and those for whom alternative therapies might be more appropriate from the outset. This kind of personalized prescribing model is already in use for certain antidepressants, anticoagulants, and oncology drugs, and the infrastructure for applying it to hair loss medicine is gradually being built.

For now, however, routine pharmacogenomic testing before starting finasteride is not standard practice in US dermatology or primary care. The evidence base, while promising, has not yet reached the threshold required for formal clinical recommendations.

Practical Implications for Patients Today

For men currently taking finasteride with underwhelming results, the existence of these genetic variables offers a medically grounded explanation — and potentially a path forward. A few considerations worth discussing with a prescribing physician:

Dose reassessment. If genetic metabolism differences are influencing drug clearance, an ultra-rapid metabolizer might theoretically benefit from a higher or more frequent dose. This is not a decision to make independently, but it is a clinically reasonable conversation to initiate.

Combination therapy. Some men with modest finasteride response see improved outcomes when minoxidil is added to their regimen. Minoxidil operates through an entirely different mechanism — stimulating blood flow and extending the anagen growth phase — and its efficacy is governed by a separate set of genetic factors, including variation in the sulfotransferase enzyme SULT1A1.

Patience calibrated to biology. Understanding that your metabolic profile may require more time to reach steady-state drug levels can reframe expectations. Some men who abandon finasteride at the six-month mark due to apparent non-response might have seen meaningful results at twelve or eighteen months.

Emerging testing options. Several US-based genetic testing services now offer pharmacogenomic panels that include CYP3A4 and androgen receptor analysis. While these are not currently validated specifically for finasteride prescribing, they may offer useful context for patients and their physicians.

The Broader Picture

The field of hair loss medicine has historically relied on population-level data to guide individual treatment decisions. Clinical trials demonstrating that finasteride outperforms placebo in large cohorts are valuable — but they describe averages, not individuals. The growing understanding of pharmacogenomics introduces a more precise framework, one in which treatment selection and dosing could eventually be tailored to the specific biological profile of each patient.

For men navigating the often discouraging experience of variable finasteride response, this science offers something meaningful: a legitimate, evidence-grounded explanation that has nothing to do with compliance failures or unrealistic expectations. Your genetics are not your destiny in hair loss treatment, but they are a significant variable — and one that medicine is only beginning to fully account for.